Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Aeterna Zentaris, Shanghai Pharma, Guangzhou Lupeng Pharma, Harbour BioMed

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Neuromyelitis Optica Spectrum Disorder pipeline constitutes 7+ key companies continuously working towards developing 8+ Neuromyelitis Optica Spectrum Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.

The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report: https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years.
• Neuromyelitis Optica Spectrum Disorder companies working in the treatment market are ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals, Guangzhou Lupeng Pharmaceutical, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others, are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment
• Emerging Neuromyelitis Optica Spectrum Disorder therapies in the different phases of clinical trials are- NDC-1308, AIM Biologicals, B001, LP-168, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.
• In October 2022, ULTOMIRIS® (ravulizumab-cwvz), compared to the external placebo arm from the pivotal SOLIRIS®PREVENT clinical trial, significantly decreased relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+)neuromyelitis optica spectrum disorder (NMOSD), according to detailed encouraging results from the Phase III CHAMPION-NMOSD trial.
• In June 2022, To assess the efficacy, pharmacokinetics, pharmacodynamics, and safety of ravulizumab in children and adolescents with aquaporin-4 antibody positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD), Alexion Pharmaceuticals started a Phase II/III, open-label, historical-controlled, single-arm, multicenter study.
• In June 2022: UPLIZNA was also given the go-ahead by the Brazilian Health Regulatory Agency (ANVISA) as a monotherapy for the treatment of adult NMOSD patients who test positive for the AQP4-IgG biomarker.
• In May 2022: The European Commission has approved the use of UPLIZNA, a medication created by Horizon Therapeutics, as a monotherapy for treating adult patients with neuromyelitis optica spectrum disease (NMOSD). No matter if a patient's AQP4-IgG test results are positive or negative, this approval is valid for all adult NMOSD patients.
• In May 2022, According to ULTOMIRIS® (ravulizumab-cwvz) Phase III study results in adults with neuromyelitis optica spectrum condition, Alexion Pharmaceuticals reported.

Neuromyelitis Optica Spectrum Disorder Overview
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that primarily affects the central nervous system, particularly the optic nerves and spinal cord. It is characterized by severe inflammation and demyelination in these areas, leading to a range of neurological symptoms. NMOSD was previously known as Devic's disease but has since been reclassified to better reflect its spectrum of manifestations.

Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:
• NDC-1308: ENDECE
• AIM Biologicals: Aeterna Zentaris
• B001: Shanghai Pharmaceuticals Holding Co., Ltd.
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
• HBM9161: Harbour BioMed
• SHR1459: Reistone Biopharma
• Telitacicept: RemeGen
• Ravulizumab: Alexion Pharmaceuticals

Neuromyelitis Optica Spectrum Disorder Route of Administration
Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Neuromyelitis Optica Spectrum Disorder Molecule Type
Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment
• Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
• Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
• Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
• Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
• Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
• Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type

DelveInsight's Neuromyelitis Optica Spectrum Disorder Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies at:
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Neuromyelitis Optica Spectrum Disorder Therapeutics Market include:
Key companies developing therapies for Neuromyelitis Optica Spectrum Disorder are - Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe, AstraZeneca, Harbour BioMed, RemeGen, Teva Pharmaceutical, TG Therapeutics, Opexa Therapeutics, and others.

Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:
The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
• Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies-
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers
• Increase in NMOSD prevalence, rising awareness among general population about NMOSD• Emergence of novel therapies are some of the important factors that are fueling the Neuromyelitis Optica Spectrum Disorder Market.

Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers
• However, dearth of skilled professionals and lack of healthcare infrastructure in developing economies, high costs for NMOSD treatment and other factors are creating obstacles in the Neuromyelitis Optica Spectrum Disorder Market growth.

Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight
• Coverage: Global
• Key Neuromyelitis Optica Spectrum Disorder Companies: ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals, Guangzhou Lupeng Pharmaceutical, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others
• Key Neuromyelitis Optica Spectrum Disorder Therapies: NDC-1308, AIM Biologicals, B001, LP-168, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others
• Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
• Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers

Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Neuromyelitis Optica Spectrum Disorder Report Introduction
2. Neuromyelitis Optica Spectrum Disorder Executive Summary
3. Neuromyelitis Optica Spectrum Disorder Overview
4. Neuromyelitis Optica Spectrum Disorder- Analytical Perspective In-depth Commercial Assessment
5. Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics
6. Neuromyelitis Optica Spectrum Disorder Late Stage Products (Phase II/III)
7. Neuromyelitis Optica Spectrum Disorder Mid Stage Products (Phase II)
8. Neuromyelitis Optica Spectrum Disorder Early Stage Products (Phase I)
9. Neuromyelitis Optica Spectrum Disorder Preclinical Stage Products
10. Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment
11. Neuromyelitis Optica Spectrum Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Neuromyelitis Optica Spectrum Disorder Key Companies
14. Neuromyelitis Optica Spectrum Disorder Key Products
15. Neuromyelitis Optica Spectrum Disorder Unmet Needs
16 . Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers
17. Neuromyelitis Optica Spectrum Disorder Future Perspectives and Conclusion
18. Neuromyelitis Optica Spectrum Disorder Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Neuromyelitis Optica Spectrum Disorder Market
https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Neuromyelitis Optica Spectrum Disorder Epidemiology
https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neuromyelitis Optica Spectrum Disorder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Mrna Based Vaccines And Therapeutics Market
https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market
DelveInsight's "Global Messenger RNA (mRNA)-based Vaccines and Therapeutics- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Global Messenger RNA (mRNA)-based Vaccines and Therapeutics, historical and forecasted epidemiology as well as the Global Messenger RNA (mRNA)-based Vaccines and Therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Papilloma Market
https://www.delveinsight.com/report-store/papilloma-market
DelveInsight's "Papilloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Papilloma, historical and forecasted epidemiology as well as the Papilloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Periodontal Disease Market
https://www.delveinsight.com/report-store/periodontal-disease-market
DelveInsight's "Periodontal Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Periodontal Disease, historical and forecasted epidemiology as well as the Periodontal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Retinoblastoma Market
https://www.delveinsight.com/report-store/retinoblastoma-market
DelveInsight's "Retinoblastoma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Retinoblastoma, historical and forecasted epidemiology as well as the Retinoblastoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-6mm-market
DelveInsight's "Skin Burns Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom).

Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market
DelveInsight's "Skin Burns Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market
DelveInsight's "Thymus Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Thymus Cancer, historical and forecasted epidemiology as well as the Thymus Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.